review

http://www.asx.com.au/asxpdf/20101026/pdf/31td3ghcgr2s93.pdf


26/10/2010


With Group revenues already approaching $1,500,000 per month (inclusive of the


and conservatively forecast to grow to around $3,000,000 a month in the next financial year, this past 20 months has been an extraordinary period of growth and achievement for the Company,


manufacturing plant in Canada that will ultimately manufacture only drugs for use in the Company?s HDA devices and ?Stirling Health? branded products.